Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZP-3601 safety and PK/PD in healthy volunteers and chronic hypoparathyroidism
NCT05239221Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in chronic hypoparathyroidism comparing AZP-3601 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 3 months. Started Sep 2020; status: completed.
02
Drugs
eneboparatide
03
Conditions
chronic hypoparathyroidism
Beyond the preview
Go deeper on NCT05239221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239221.